06.28.2010
June 28, 2010 Marcadia Biotech, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the companies have signed a development and exclusive license agreement for Marcadia's short-acting glucagon program
05.03.2010
May 3, 2010; Industry Veteran of 37 Years Joins Board After Retierment from Pfizer
02.17.2010
February 17, 2010 Marcadia Initiates Phase 1 Clinical Trial of GLP-1/GIP Dual Agonist MAR701
11.13.2009
November 13, 2009; World-Class Series Set to Sustain
and Accelerate Biotech Vision of Late Co-founder